RPRX
NASDAQ HealthcareRoyalty Pharma plc - Class A Ordinary Shares
Biotechnology
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.
๐ Market Data
| Price | $58.40 |
|---|---|
| Volume | 397,790 |
| Market Cap | 33.81B |
| Dividend Yield % | 1.63% |
| Beta | 0.430 |
| RSI (14-Day) | 26.7 Oversold |
| 200-Day MA | $50.07 |
| 50-Day MA | $59.32 |
| 52-Week High | $64.38 |
| 52-Week Low | $34.63 |
| P/E Ratio | 31.45 |
| Forward P/E | 10.20 |
| Price / Book | 3.82 |
๐ฏ Investment Strategy Scores
RPRX scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Institutional Whale (80/100) โ this strategy Large-cap, institutional-quality stocks.
Lowest fit among scored strategies: ๐ Over-Hyped (28/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find RPRX in your text
Paste any article, transcript, or post โ the tool will extract RPRX and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-09-24.